You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

The 2DR Era

Times are changing | 2DR Era

No one should take more medicines than they need

2DR: Meeting a clinical need

The HIV treatment landscape has changed dramatically over the past 30 years, with each decade serving as a foundation for the next to build upon. Today marks the beginning of the next era in HIV therapy...THE 2DR ERA.

Timeline of HIV Treatment
  • A 20-year-old starting a 3-drug regimen may be on therapy for nearly 6 DECADES, which translates to MORE THAN 60,000 DOSES of individual medications 6

See how a 2DR can benefit your patients

Tivicay is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-Infected adults, adolescents and children above 6 years of age. 7

Epivir is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children. 8

Juluca is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for ≥6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI. 9

Tivicay + lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.

DDIs=drug-drug interactions.

Learn More

Explore dolutegravir based, 2-drug regimens for your diverse patient needs.

References:

  1. A timeline of HIV/AIDS. https://www.hiv.gov/sites/default/files/aidsgov-timeline.pdf. Accessed July 2019.
  2. Llibre JM, et al. J Antimicrob Chemother. 2016;71:856-861.
  3. Antiretroviral drugs used in the treatment of HIV infection. http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm. Accessed July 2019.
  4. ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single pill for the treatment of HIV [news release]. London, UK: ViiV Healthcare group of companies; May 21, 2018. https://www.viivhealthcare.com/en-gb/media/press-releases/2018/may/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/. Accessed July 2019.
  5. ViiV Healthcare. 2018 Press Release. ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine. Available at: https://www.viivhealthcare.com/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine.aspx Accessed July 2019.
  6. The Antiretroviral Therapy Cohort Collaboration. Lancet HIV. 2017;4:e349-e356.
  7. TIVICAY Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/tivicay-film-coated-tablets-33993/, last accessed July 2019.
  8. EPIVIR Summary of Product Characteristics.  Available from: https://www.medicines.ie/medicines/epivir-film-coated-tablets-150mg-32047/, last accessed July 2019.
  9. JULUCA Summary of Product Characteristics.  Available from: https://www.medicines.ie/medicines/juluca-50-mg-25-mg-film-coated-tablets-34548/, last accessed July 2019.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.